140 related articles for article (PubMed ID: 31463638)
21. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
22. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
24. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.
David JM; Owens TA; Barwe SP; Rajasekaran AK
Mol Cancer Ther; 2013 Nov; 12(11):2296-307. PubMed ID: 24006494
[TBL] [Abstract][Full Text] [Related]
25. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
Nakayama Y; Enomoto D; Yamamoto K; Takara K
Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
27. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
[TBL] [Abstract][Full Text] [Related]
28. Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.
Yangyun W; Guowei S; Shufen S; Jie Y; Rui Y; Yu R
Gene; 2022 Jan; 809():145992. PubMed ID: 34648917
[TBL] [Abstract][Full Text] [Related]
29. G Protein Alpha S Subunit Promotes Cell Proliferation of Renal Cell Carcinoma with Involvement of Protein Kinase A Signaling.
Zhang B; Sun N; Mu X; Zhi L; Zhai L; Jiang Y; Fu Z; Yao Z
DNA Cell Biol; 2017 Mar; 36(3):237-242. PubMed ID: 28051330
[TBL] [Abstract][Full Text] [Related]
30. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
32. MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40.
Zhang H; Wei P; Lv W; Han X; Yang J; Qin S; Zhang Y
Cell Transplant; 2019 Dec; 28(1_suppl):37S-50S. PubMed ID: 31813279
[TBL] [Abstract][Full Text] [Related]
33. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
35. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
[TBL] [Abstract][Full Text] [Related]
36. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
[TBL] [Abstract][Full Text] [Related]
37. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
39. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
[TBL] [Abstract][Full Text] [Related]
40. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Wu WS; Chien CC; Chen YC; Chiu WT
PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
